Enhanced prognostic signature for lung adenocarcinoma through integration of adjacent normal and tumor gene expressions
View abstract on PubMed
Summary
This summary is machine-generated.Combining tumor and normal tissue gene expression data improves lung adenocarcinoma prognostic signatures. A combined model demonstrated superior generalizability and clinical relevance compared to models using only tumor or normal tissues.
Area Of Science
- Oncology
- Bioinformatics
- Genomics
Background
- Cancer prognosis signatures traditionally use tumor or normal tissue gene expression.
- The benefit of combining both tissue types for prognostic signatures is unexplored.
Purpose Of The Study
- To develop and evaluate prognostic models for lung adenocarcinoma (LUAD) using tumor, normal, and combined gene expression profiles.
- To assess the generalizability and clinical significance of these models.
Main Methods
- Developed three LUAD prognostic models using The Cancer Genome Atlas (TCGA) data: tumor-derived, normal-derived, and combined (COM).
- Validated models on TCGA and three independent datasets, analyzing overall survival, discrimination, and calibration.
- Assessed clinical significance using clinical features and GSE229705 validation.
Main Results
- The combined (COM) model showed the best performance on independent datasets and superior overall survival prediction.
- COM-derived risk scores demonstrated the strongest clinical significance and generalizability.
- Tumor-derived models showed potential overfitting on the primary dataset; normal-derived models performed poorly.
Conclusions
- Combining tumor and normal gene expression data enhances prognostic signature performance and generalizability for LUAD.
- The COM model offers a more clinically relevant and robust approach to cancer prognosis.

